Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Athanasios Tragiannidis, Anastasia Gkampeta, Maria Vousvouki, Eleni Vasileiou & Andreas H. Groll. (2021) Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions. Expert Opinion on Drug Safety 20:9, pages 1061-1074.
Read now
Read now
Meenakshi Balhara, Renu Chaudhary, Sonam Ruhil, Bharat Singh, Nisha Dahiya, Virinder S. Parmar, Pawan. K. Jaiwal & Anil K. Chhillar. (2016) Siderophores; iron scavengers: the novel & promising targets for pathogen specific antifungal therapy. Expert Opinion on Therapeutic Targets 20:12, pages 1477-1489.
Read now
Read now
Rebecca S Campbell, Paresh Chaudhari, Harlen D Hays, Robert J Taylor, Brian H Nathanson, Samuel A Bozzette & David L Horn. (2013) Outcomes associated with conventional versus lipid-based formulations of amphotericin B in propensity-matched groups. ClinicoEconomics and Outcomes Research 5, pages 507-517.
Read now
Read now
Seyedmojtaba Seyedmousavi, Johan W Mouton, Paul E Verweij & Roger JM Brüggemann. (2013) Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis. Expert Review of Anti-infective Therapy 11:9, pages 931-941.
Read now
Read now
Carlos Rubio-Terrés & Santiago Grau. (2010) Pharmacoeconomics of voriconazole. Expert Opinion on Pharmacotherapy 11:6, pages 877-887.
Read now
Read now
Charles Craddock, James Anson, Patrick Chu, Andrew Dodgson, Nick Duncan, Cesar Gomez, Jayesh Mehta, Shalal Sadullah, Chinari Subudhi & John-Liu Yin. (2010) Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex. Expert Opinion on Drug Safety 9:1, pages 139-147.
Read now
Read now